Literature DB >> 31668555

Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner.

Antony Cougnoux1, Mason Fellmeth1, Tansy Gu2, Cristin D Davidson2, Alana L Gibson2, William J Pavan2, Forbes D Porter3.   

Abstract

Niemann-Pick disease, type C1 (NPC1) is a rare neurodegenerative lysosomal storage disease with a wide spectrum of clinical manifestation. Multiple genetic factors influence the NPC1 mouse phenotype, but very little attention has been given to prenatal environmental factors that might have long-term effects on the neuroinflammatory component of NPC1 pathology. Studies in other mouse models of cerebellar ataxia have shown that developmental exposures lead to Purkinje neuron degeneration later in life, suggesting that environmental exposures during development can impact cerebellar biology. Thus, we evaluated the potential effect of maternal immune activation (MIA) on disease progression in an Npc1 mouse model. The MIA paradigm used mimics viral infection using the toll like receptor 3 agonist polyinosinic-polycytidilic acid during gestation. Through phenotypic and pathologic tests, we measured motor and behavioral changes as well as cerebellar neuroinflammation and neurodegeneration. We observed a gender and genotype dependent effect of MIA on the cerebellum. While the effects of MIA have been previously shown to primarily affect male progeny, we observed increased sensitivity of female mutant progeny to prenatal exposure to treatment with polyinosinic-polycytidilic acid. Specifically, prenatal MIA resulted in female NPC1 mutant progeny with greater motor deficits and a corresponding decrease in cerebellar Purkinje neurons. Our data suggest that prenatal environmental exposures may be one factor contributing to the phenotypic variability observed in individuals with NPC1. Published by Elsevier Inc.

Entities:  

Keywords:  Lysosomal storage disease; Maternal immune activation; Mouse model; Neurodegeneration; Niemann-pick disease, type C1; Purkinje neurons

Mesh:

Substances:

Year:  2019        PMID: 31668555      PMCID: PMC7002177          DOI: 10.1016/j.ymgme.2019.10.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  32 in total

1.  A modifier of Niemann Pick C 1 maps to mouse chromosome 19.

Authors:  J Zhang; R P Erickson
Journal:  Mamm Genome       Date:  2000-01       Impact factor: 2.957

2.  Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.

Authors:  A Cougnoux; S Clifford; A Salman; S-L Ng; J Bertin; F D Porter
Journal:  Mol Genet Metab       Date:  2018-10-30       Impact factor: 4.797

3.  Subclinical course of adult visceral Niemann-Pick type C1 disease. A rare or underdiagnosed disorder?

Authors:  L Dvorakova; J Sikora; M Hrebicek; H Hulkova; M Bouckova; L Stolnaja; M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-06-26       Impact factor: 4.982

4.  A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele.

Authors:  Maria Praggastis; Brett Tortelli; Jessie Zhang; Hideji Fujiwara; Rohini Sidhu; Anita Chacko; Zhouji Chen; Chan Chung; Andrew P Lieberman; Jakub Sikora; Cristin Davidson; Steven U Walkley; Nina H Pipalia; Frederick R Maxfield; Jean E Schaffer; Daniel S Ory
Journal:  J Neurosci       Date:  2015-05-27       Impact factor: 6.167

5.  Maternal immune activation alters fetal brain development through interleukin-6.

Authors:  Stephen E P Smith; Jennifer Li; Krassimira Garbett; Karoly Mirnics; Paul H Patterson
Journal:  J Neurosci       Date:  2007-10-03       Impact factor: 6.167

6.  Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.

Authors:  Antony Cougnoux; Rebecca A Drummond; Amanda L Collar; James R Iben; Alexander Salman; Harrison Westgarth; Christopher A Wassif; Niamh X Cawley; Nicole Y Farhat; Keiko Ozato; Michail S Lionakis; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2018-06-15       Impact factor: 6.150

7.  Activation of the maternal immune system alters cerebellar development in the offspring.

Authors:  Limin Shi; Stephen E P Smith; Natalia Malkova; Doris Tse; Yixuan Su; Paul H Patterson
Journal:  Brain Behav Immun       Date:  2008-08-09       Impact factor: 7.217

8.  A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia.

Authors:  Stephan J Guyenet; Stephanie A Furrer; Vincent M Damian; Travis D Baughan; Albert R La Spada; Gwenn A Garden
Journal:  J Vis Exp       Date:  2010-05-21       Impact factor: 1.355

9.  Gender-dependent effects of maternal immune activation on the behavior of mouse offspring.

Authors:  Ingrid C Y Xuan; David R Hampson
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

10.  Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.

Authors:  D Mattei; A Ivanov; C Ferrai; P Jordan; D Guneykaya; A Buonfiglioli; W Schaafsma; P Przanowski; W Deuther-Conrad; P Brust; S Hesse; M Patt; O Sabri; T L Ross; B J L Eggen; E W G M Boddeke; B Kaminska; D Beule; A Pombo; H Kettenmann; S A Wolf
Journal:  Transl Psychiatry       Date:  2017-05-09       Impact factor: 6.222

View more
  3 in total

Review 1.  Impact of Sex and Age on the Mevalonate Pathway in the Brain: A Focus on Effects Induced by Maternal Exposure to Exogenous Compounds.

Authors:  Claudia Tonini; Marco Segatto; Valentina Pallottini
Journal:  Metabolites       Date:  2020-07-25

Review 2.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

3.  Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann-Pick Disease, Type C1.

Authors:  Niamh X Cawley; Anna T Lyons; Daniel Abebe; Christopher A Wassif; Forbes D Porter
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.